Immix Biopharma Earnings Call Transcripts
Fiscal Year 2026
-
NXC-201 produced 40 complete responses among 45 patients; including MRD-negative patients, 44/45 were in CR or MRD-negative, with further CR conversions anticipated. Median CRS lasted one day, with no high-grade CRS or neurotoxicity reported.
-
NXC-201, a novel CAR T therapy for AL amyloidosis, demonstrates rapid, deep responses and a favorable safety profile, with regulatory designations supporting accelerated review. A pivotal readout and BLA submission are expected, and a Phase III frontline trial is underway.
Fiscal Year 2025
-
NXC-201 CAR T-cell therapy shows rapid, deep, and durable responses in relapsed/refractory AL amyloidosis, with a favorable safety profile and potential for outpatient use. If approved, it could address a major unmet need for over 20,000 U.S. patients.